FDA Warns Drugmakers Over Missing Clinical Trial Results
The FDA sent letters to 2,200+ companies in 2026 warning of fines for failing to submit clinical trial results to ClinicalTrials.gov.
3 articles tagged "Drug Development"
The FDA sent letters to 2,200+ companies in 2026 warning of fines for failing to submit clinical trial results to ClinicalTrials.gov.
A four-month FDA meeting cancellation proved fatal for Kezar Life Sciences, highlighting how regulatory delays can devastate small biotech companies.
Kezar Life Sciences is winding down after FDA meeting cancellations disrupted its autoimmune hepatitis drug program, driving investors to withdraw funding.